ArticleBMC nephrology2026
Long-term survival and mortality characteristics of patients with ANCA-associated vasculitis on maintenance hemodialysis: a propensity score-matched study from the Wuhan registry (2017-2025).
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRegistry-based data on the long-term survival of ANCA-associated vasculitis (AAV) patients on maintenance hemodialysis (MHD) in China are limited, particularly across the COVID-19 pandemic period.
methodsData were obtained from the Wuhan Dialysis Registry (2017–2025), including 9,430 MHD patients with complete data, of whom 54 (0.57%) had AAV. Propensity score matching (1:3) generated 54 AAV and 162 non-AAV patients. All-cause survival was compared using Kaplan-Meier methods. Cox proportional hazards models were used to evaluate mortality risk factors among AAV patients.
resultsOverall survival was comparable between AAV and matched non-AAV patients. 1-, 2-, 3-, and 5-year survival rates were 91.8%, 84.2%, 75.2%, and 67.5% in AAV, versus 94.5%, 85.5%, 81.2%, 67.7% in non-AAV patients (P = 0.737). Among 12 deaths in AAV patients (median age 74.0 years, median dialysis vintage 21.0 months), infection was the leading cause (8/12, 66.7%), including COVID-19 in 3 cases (25.0%); no deaths were attributed to AAV relapse. Univariable Cox regression identified that older age (HR 1.09, P = 0.028), lower hemoglobin (HR 0.96, P = 0.041), and central venous catheter use (HR 4.01, P = 0.038) were significantly associated with increased mortality in AAV patients. Multivariable analysis was not performed due to limited events (n = 12).
conclusionsIn this registry-based cohort, overall survival was comparable between AAV and non-AAV patients on maintenance hemodialysis. Infection was the leading cause of death, with no deaths attributed to AAV relapse. These findings highlight the critical importance of infection prevention strategies in this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.